ch.oddb.org
 
Apotheken | Doctor | Drugs | Hospital | Interactions | MiGeL | Registration owner | Services
Information for professionals for Cinnageron®:Streuli Pharma AG
Complete information for professionalsDDDPrint 
Composition.Galenic FormIndication.UsageContra IndicationWarning restrictions.Interactions.Pregnancy
Driving abilityUnwanted effectsOverdoseEffectsPharm.kinetikPreclinicalOther adviceSwissmedic-Nr.
Registration ownerLast update of information 
N07CA02 - CinnarizineATC-DDD Version 2016. Source: WHO
N - Nervous System
 
N07 - Other Nervous System Drugs

This group comprises other nervous system drugs, which cannot be classified in the preceding 2nd levels in ATC group N.

N07C - Antivertigo Preparations

This group comprises agents mainly used in the treatment of vertigo.
See also:
A04A - Antiemetics and antinauseants
C04AX - Other peripheral vasodilators
N02C - Antimigraine preparations
N05A - Antipsychotics
R06A - Antihistamines for systemic use

The DDDs are based on treatment of vestibular symptoms.

N07CA - Antivertigo Preparations

Cinnarizine in combination with diphenhydramine teoclate or dihydroergocristine are classified in N07CA52.

The DDD for the N07CA52 refers to cinnarizine and is based on the combination of cinnarizine and diphenhydramine teoclate.

N07CA02 - Cinnarizine
DoseRoute of administrationNote
 O 
2025 ©ywesee GmbH
Settings | Help | FAQ | Login | Contact | Home